ArticleFood science & nutrition2026
Traditional Chinese Herbal Formula XuMingZhuSan Alleviates Neuronal Ferroptosis in Rats After Stroke by Activating the NRF2/GPX4/SLC7A11 Pathway.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reported the efficacy of Traditional Chinese herbal formula XuMingZhuSan (XMZS) in stroke. Middle cerebral artery occlusion (MCAO) rat model was constructed and treated by XMZS and ML385. Brain sections of rats underwent histologic staining methods to assess brain infarction, neuronal and mitochondrial damage, and reactive oxygen species (ROS) production. Oxygen-glucose deprivation/reperfusion (OGD/R)-induced hippocampal neurons were treated with XMZS and ML385. Apoptosis, ROS, mitochondrial membrane potential, and lipid peroxidation in hippocampal neurons were monitored by TUNEL, DCFH-DA, JC-1, and C11-Bodipy staining. Ferroptosis-related indicators in brains and hippocampal neurons were assayed using commercial kits. NRF2/GPX4/SLC7A11 pathway activity within brains and hippocampal neurons was assessed by Western blotting. In MCAO rats, XMZS improved neurological function; reduced cerebral infarction volume; relieved neuronal damage in the cortex and hippocampal CA1 and CA3 regions, and mitochondrial damage within the brain; suppressed ROS in the cortex and hippocampal CA1 and CA3 regions; decreased Fe and MDA contents within the brain; increased SOD and GSH within the brain; and activated NRF2/GPX4/SLC7A11 pathway within the brain. These influences induced by XMZS on MCAO rats were eliminated by ML385. XMZS mitigated apoptosis of OGD/R-induced hippocampal neurons; reduced LDH activity and ROS; declined Fe and MDA contents; raised SOD and GSH levels; elevated mitochondrial membrane potential; suppressed lipid peroxidation; and activated NRF2/GPX4/SLC7A11 pathway. ML385 reversed these effects of XMZS on the OGD/R-induced hippocampal neurons. XMZS may activate NRF2/GPX4/SLC7A11 pathway to treat stroke by attenuating neuronal ferroptosis and is applicable in clinical management of stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.